Parkinson's Disease Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | Annovis Bio, Cerevel Therapeutics, Roche,

DelveInsight's, "Parkinson's Disease- Pipeline Insight, 2025" report provides comprehensive insights about 130+ companies and 150+ pipeline drugs in Parkinson's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
According to DelveInsight, over 130 prominent companies are actively involved in developing more than 150 therapeutic candidates for the treatment of Parkinson's disease.

Parkinson's Disease Overview:

Parkinson's disease (PD) is a chronic and progressive neurological condition that primarily impairs movement due to the degeneration of dopamine-producing neurons in the substantia nigra, a brain region essential for motor control. It usually affects individuals over the age of 60, though it can appear earlier, and is the second most prevalent neurodegenerative disorder after Alzheimer's disease. Symptoms differ significantly between individuals and are often challenging to predict or manage.

Motor symptoms typically include tremors, muscle stiffness, slowed movement (bradykinesia), and impaired balance, increasing the risk of falls. In addition, non-motor symptoms such as sleep disturbances, depression, anxiety, and cognitive decline are frequently observed.

The exact cause of PD remains unknown, but both genetic mutations (such as in the LRRK2 and SNCA genes) and environmental exposures (like pesticides or heavy metals) are believed to play a role. On a cellular level, PD is marked by the buildup of alpha-synuclein protein within Lewy bodies and a shortage of dopamine, which disrupts normal neurotransmitter activity. Diagnosis is primarily clinical but may be supported by imaging tools like DaTscan.

While there is no cure, treatment aims to control symptoms. Levodopa is the most commonly used drug, often combined with dopamine agonists and MAO-B inhibitors. In more advanced stages, deep brain stimulation (DBS) may offer additional relief. Supportive therapies such as physical and occupational therapy, along with lifestyle modifications, are essential for maintaining quality of life.

Request for a detailed insights report on Parkinson's Disease pipeline insights [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

"Parkinson's Disease Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Parkinson's Disease Therapeutics Market.

Key Takeaways from the Parkinson's Disease Pipeline Report

*
DelveInsight's Parkinson's Disease pipeline report depicts a robust space with 130+ active players working to develop 150+ pipeline therapies for Parkinson's Disease treatment.

*
In December 2025, AbbVie announced positive topline results from the Phase III TEMPO-2 trial of tavapadon, a first-in-class D1/D5 partial agonist being investigated as a once-daily treatment for Parkinson's disease. The trial met both primary and secondary endpoints, showing significant improvements in motor function. AbbVie plans to submit a New Drug Application (NDA) to the FDA in 2025.

*
In November 2025, Sunbird Bio revealed new data demonstrating that its diagnostic technology could accurately classify blood samples from Parkinson's disease patients with 86% accuracy by detecting aggregated alpha-synuclein proteins.

*
In October 2025, AbbVie announced FDA approval for VYALEV (foscarbidopa/foslevodopa), a treatment for motor fluctuations in adults with advanced Parkinson's disease. This marks the approval of the first 24-hour continuous subcutaneous infusion of a levodopa-based therapy.

*
Key Parkinson's Disease companies such as Annovis Bio, Cerevel Therapeutics, Roche, Inhibikase Therapeutics, Inc, Gain Therapeutics, Neuronascent, ANEW MEDICAL, Longevity Biotech, Minerva Neurosciences/Mitsubishi Tanabe Pharma Corporation, Tetraneuron, Kallyope, BlueRock Therapeutics LP, Neuraly, Peptron/Yuhan Corporation, Genentech, Kissei Pharmaceutical, Asklepios BioPharmaceutical, Alkahest, Modag, Intra-Cellular Therapies, Living Cell Technologies, MedImmune, and others are evaluating new drugs for Parkinson's Disease to improve the treatment landscape.

*
Promising Parkinson's Disease pipeline therapies in various stages of development include Buntanetap, Tavapadon, Prasinezumab, Risvodetinib, GT 02287, NNI 362, and others.

Parkinson's Disease Pipeline Analysis

The report provides insights into:

*
The report provides detailed insights into the key companies that are developing therapies in the Parkinson's Disease Market.

*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Parkinson's Disease treatment.

*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.

*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.

*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Parkinson's Disease market.

Download our free sample page report on Parkinson's Disease pipeline insights [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Parkinson's Disease Emerging Drugs

*
Buntanetap: Annovis Bio

*
Tavapadon: Cerevel Therapeutics

*
Prasinezumab: Roche

*
Risvodetinib: Inhibikase Therapeutics, Inc

*
GT 02287: Gain Therapeutics

*
NNI 362: Neuronascent

Parkinson's Disease Companies

Over 130 key companies are working on developing therapies for Parkinson's disease. Among them, Annovis Bio is one of the companies with drug candidates for Parkinson's disease in the most advanced stage, Phase III.

DelveInsight's report covers around 150+ products under different phases of clinical development like

*
Late stage products (Phase III)

*
Mid-stage products (Phase II)

*
Early-stage product (Phase I) along with the details of

*
Pre-clinical and Discovery stage candidates

*
Discontinued & Inactive candidates

Parkinson's Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

*
Intravenous

*
Subcutaneous

*
Oral

*
Intramuscular

Parkinson's Disease Products have been categorized under various Molecule types such as

*
Monoclonal antibody

*
Small molecule

*
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Parkinson's Disease Therapies and Key Companies: Parkinson's Disease Clinical Trials and advancements [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Parkinson's Disease Pipeline Therapeutic Assessment

- Parkinson's Disease Assessment by Product Type

- Parkinson's Disease By Stage

- Parkinson's Disease Assessment by Route of Administration

- Parkinson's Disease Assessment by Molecule Type

Download Parkinson's Disease Sample report to know in detail about the Parkinson's Disease treatment market @ Parkinson's Disease Therapeutic Assessment [https://www.delveinsight.com/sample-request/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Table of Content

1. Report Introduction

2. Executive Summary

3. Parkinson's Disease Current Treatment Patterns

4. Parkinson's Disease - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Parkinson's Disease Late-Stage Products (Phase-III)

7. Parkinson's Disease Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Parkinson's Disease Discontinued Products

13. Parkinson's Disease Product Profiles

14. Parkinson's Disease Key Companies

15. Parkinson's Disease Key Products

16. Dormant and Discontinued Products

17. Parkinson's Disease Unmet Needs

18. Parkinson's Disease Future Perspectives

19. Parkinson's Disease Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Parkinson's Disease Pipeline Reports Offerings [https://www.delveinsight.com/report-store/parkinsons-disease-pipeline-insights?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=parkinsons-disease-clinical-and-nonclinical-studies-key-companies-therapeutic-assessment-emerging-therapies-treatment-algorithm-and-pipeline-analysis-annovis-bio-cerevel-therapeutics-roche]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.